HilleVax, Inc. (NASDAQ:HLVX) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC lifted its position in HilleVax, Inc. (NASDAQ:HLVX) by 61.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,145 shares of the company’s stock after purchasing an additional 6,916 shares during the period. SG Americas Securities LLC’s holdings in HilleVax were worth $38,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in HLVX. Braidwell LP acquired a new position in HilleVax during the third quarter worth $1,873,000. Verition Fund Management LLC acquired a new position in HilleVax during the third quarter worth $331,000. Zacks Investment Management raised its position in HilleVax by 411.9% during the third quarter. Zacks Investment Management now owns 92,803 shares of the company’s stock worth $163,000 after acquiring an additional 74,673 shares during the period. Jane Street Group LLC raised its position in HilleVax by 81.7% during the third quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock worth $139,000 after acquiring an additional 35,546 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in HilleVax during the third quarter worth $126,000. 86.42% of the stock is currently owned by institutional investors and hedge funds.

HilleVax Stock Up 1.6 %

HilleVax stock opened at $1.86 on Friday. HilleVax, Inc. has a 52-week low of $1.55 and a 52-week high of $20.22. The firm has a market capitalization of $92.65 million, a price-to-earnings ratio of -0.60 and a beta of 0.74. The company has a fifty day simple moving average of $1.94 and a 200-day simple moving average of $1.87.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.